![Matthew Klein](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Matthew Klein
Chief Executive Officer at
PTC THERAPEUTICS, INC.
Net worth: 30 M $ as of 2026-05-30
Profile
Matthew B. Klein is President, Chief Executive Officer & Director at PTC Therapeutics, Inc. since 2023.
He is an Independent Director at ClearPoint Neuro, Inc. since 2020.
He serves as Director at PTC Therapeutics International Ltd. and Clinical Associate Professor at Stanford University.
Former roles include Chairman-Restorative Burn Surgery at the University of Washington, Director at BioElectron Technology Corp.
from 2019 to 2020, and Chief Medical Officer & Senior Vice President at Edison Pharmaceuticals, Inc. Education includes undergraduate studies at the University of Pennsylvania, a doctorate from Yale University, and graduate education at UW School of Public Health.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-05-13 | 393,998 ( 0.47% ) | 29 M $ | 2026-05-30 | |
| 2026-05-20 | 46,935 ( 0.16% ) | 594 666 $ | 2026-05-30 |
Matthew Klein active positions
| Companies | Position | Start |
|---|---|---|
| CLEARPOINT NEURO, INC. | Director/Board Member | 2020-04-15 |
| PTC THERAPEUTICS, INC. | Chief Executive Officer | 2023-03-21 |
Stanford University
 Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
PTC Therapeutics International Ltd.
 PTC Therapeutics International Ltd. PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors. | Director/Board Member | - |
Former positions of Matthew Klein
| Companies | Position | End |
|---|---|---|
BioElectron Technology Corp.
 BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic treatments for inherited mitochondrial diseases primarily affecting children | Chief Executive Officer | 2018-12-31 |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Edison Pharmaceuticals, Inc.
 Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat mitochondrial diseases | Chief Tech/Sci/R&D Officer | - |
Training of Matthew Klein
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
63
1st degree connections
10
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Edison Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs to treat mitochondrial diseases | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clearpoint Neuro, Inc.
 Clearpoint Neuro, Inc. Medical SpecialtiesHealth Technology Develops and markets bio technology and surgical products | Health Technology |
PTC Therapeutics International Ltd.
PTC Therapeutics International Ltd. PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors. | |
BioElectron Technology Corp.
BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services Develops therapeutic treatments for inherited mitochondrial diseases primarily affecting children | Commercial Services |
UW School of Public Health
 UW School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Matthew Klein
